Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biomarin Pharmaceuticals (NQ: BMRN )

93.45 +1.78 (+1.95%)
Streaming Delayed Price Updated: 10:59 AM EDT, Mar 20, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 296,522
Open 92.07
Bid (Size) 93.42 (2)
Ask (Size) 93.48 (2)
Prev. Close 91.67
Today's Range 91.23 - 93.76
52wk Range 70.73 - 117.77
Shares Outstanding 183,352,255
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
After FDA Delays Hemophilia Gene Therapy, BioMarin's Dwarfism Drug Under FDA Review For Expanded Use
 
Via Benzinga
Why BioMarin Shares Are Plunging Today?
Biomarin Pharmaceutical Inc (NASDAQ: BMRN) shares are falling in reaction to positive data from BridgeBio Pharma Inc's (NASDAQ: BBIO) dwarfism drug, heating the competition. 
Via Benzinga

Performance

YTD
-7.11%
-7.11%
1 Month
-13.72%
-13.72%
3 Month
-12.34%
-12.34%
6 Month
+6.56%
+6.56%
1 Year
+15.15%
+15.15%

More News

Read More
BridgeBio Soars 64% And Breaks Out After Smashing Expectations In A Dwarfism Study
Via Investor's Business Daily
Kala Pharmaceuticals Stock Showing Rising Market Leadership; Earns 83 RS Rating
Via Investor's Business Daily
uniQure Stock Trying To Close In On Key Technical Measure
Via Investor's Business Daily
BioMarin Hints Probable Delay For US Approval For Roctavian, But Analyst Convinced For Transformative 2023
Via Benzinga
Preview: Biomarin Pharmaceutical's Earnings
Via Benzinga
Analyst Ratings for Biomarin Pharmaceutical
Via Benzinga
BioMarin Valuation Fair, But Expectations From Hemophilia Therapy Too High, Says Analyst
Via Benzinga
Earnings Scheduled For February 27, 2023
Via Benzinga
What 5 Analyst Ratings Have To Say About Biomarin Pharmaceutical
Via Benzinga
6 Analysts Have This to Say About Biomarin Pharmaceutical
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 22, 2023
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 21, 2023
Via Benzinga
2 Top Biotech Stocks Defying the Bear Market
Via The Motley Fool
3 Prime Healthcare Takeover Targets
Via The Motley Fool
Moderna Stock Getting Closer To Key Technical Benchmark
Via Investor's Business Daily
BioRestorative (NASDAQ: BRTX) Ramps Up Production In Anticipation Of Positive Phase 2 Results
Via Benzinga
3 Drug Stocks With Promising Pipelines for 2023
Via InvestorPlace
Cramer Is Holding This Biotech Stock
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 30, 2023
Via Benzinga
Vertex Pharmaceuticals Stock Sees Rising Relative Strength
Via Investor's Business Daily
BioMarin's Growth Prospects Soar with Potential Voxzogo and Roctavian Launches, Analyst Raises Price Target
Via Benzinga
Top Picks For 2023: Catalyst Pharmaceuticals
Via Talk Markets
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.